The first adult patient has been dosed in a Phase 1/2 clinical trial evaluating FCX-013 (Castle Creek Biosciences, Inc) for the treatment of moderate to severe localized scleroderma, according to a press release.
"Dosing the first patient is an important milestone in the clinical development program for FCX-013, which we believe has the potential to be the first therapy to treat excessive collagen deposition at the site of localized scleroderma lesions in the skin and soft tissue," said John Maslowski, Chief Executive Officer of Castle Creek Biosciences in the press release. "Our hope is to relieve the debilitating, painful impact of localized scleroderma in patients who currently have limited treatment options."
The open label, single cohort Phase 1/2 clinical trial will enroll up to 10 patients with moderate to severe localized scleroderma.
Read the full press release here.